summari morn report beat
provid outlook first time well direct
commentari compani turnaround ceo bryan
hanson underway focu call key
takeaway track per plan restor full suppli
key brand fda re-inspect occur week
result addit observ address
rosa total knee on-track late limit launch
maintain month time-horizon turnaround
return market growth rate better adjust
estim better reflect compani growth trajectori
base approxim new ep
earn revis revenu estim higher
reflect zbh beat outlook includ higher fx
benefit continu expect neg growth day-adjust
basi modest posit growth meaning
improv underli basi expect
deliv growth thereaft
revenu estim
adjust ep estim unchang
fall mid-point compani guidanc
adjust ep estim beyond lower better
reflect assumpt gross margin oper leverag
result beat expect revenu
y/i y/i ex-fx exceed guidanc rang
y/i ex-fx compar
consensu estim respect fx
tailwind quarter guidanc
partial off-set headwind due one less sell day
adjust two item estim zbh organ sale
declin y/i y/i organ
growth deliv adjust partial addit sell day
manag note call recon market
like sequenti pend syk result price
quarter versu volum
versu adjust ep
y/i top-end compani guidanc rang
y/i exceed consensu
estim respect
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort non-recur item
compani prioriti stock list
compani data secur llc estim reuter
continu previou page
outlook direct color provid provid full year outlook
first time compani look revenu rang y/i
y/i ex-fx bracket prior estim consensu estim
fx expect tailwind year net impact sell day
neutral compani expect return posit growth aid restor full suppli
key product line ceo bryan hanson reiter call expect acceler top-lin
growth market growth rate weight averag better next month period
growth acceler expect driven us
adjust ep expect rang y/i bracket
estim put consensu top-end rang manag
expect ep reflect improv top-lin materi benefit gross margin modest
accret sg slightli higher oper margin versu guid lower
tax rate revis expect deliv
major use toward debt repay
note margin make good progress consist volum product
warsaw north campu facil also continu incur increas level manufactur qualiti
cost suppli fulli restor associ drop cost fact
anticip gross margin pressur capit invest cost
warsaw facil flow cog inventori sold mean
gross margin pressur month cost incur worth note
remain focus qualiti remedi suppli recoveri effort like begin drive
product improv sometim next year
track restor suppli plan encourag note suppli level
north campu facil track plan sequenti improv anticip
fact ceo bryan hanson express higher confid versu quarter ago zbh abil restor full
suppli key brand within hip knee set categori begin alreadi begun
see increas suppli level impli on-going initi gain traction said ceo
bryan hanson note risk suppli recoveri mitig continu present
includ execut relianc consist extern suppli volum talent retent stabil north
campu facil execut on-going qualiti remedi plan warsaw overal progress suppli
receiv addit observ earlier week fda conclud inspect
zbh warsaw north campu facil note addit observ recal facil
last inspect late began zbh two-year remedi plan fda re-inspect much
await evalu progress make remedi front process
evalu formal respons recent observ made fda submit
come week manag note observ fewer receiv last time
around resolut new observ remain top prioriti news encourag
note pma review could risk unlik lead increment
portfolio manag may come sooner interest portfolio manag key part
manag prepar commentari call mr hanson note busi stabil
short-term would like quickli get activ portfolio manag drive compani
weight averag growth first step taken hire rachel
ellingson former head strategi stj receiv join new svp strategi mr
hanson note portfolio manag high list think compani could look divest
dental busi see note date march wsj report potenti sale dental
increas depth exist busi line like even look add new adjac
global recon market growth like deceler big four recon hip knee
implant compani report result plug number
market model use estim other snn estim global recon market
deceler sequenti y/i versu includ
deceler us y/i versu global knee market deceler
sequenti y/i versu includ deceler us
y/i versu global hip market like deceler sequenti
y/i versu includ improv sequenti us
y/i versu
segment result stack follow sale growth repres y/i ex-fx rate
versu adjust one less sell day partial addit day
equat estim headwind tailwind respect segment
zbh result stack follow
knee sale versu compar estim
growth driven europ middl east africa emea region off-set asia
pacif america knee price versu volum
versu benefit continu uptak persona partial
knee like off-set competit headwind us adjust sell day estim
america y/i
hip sale versu compar estim
growth driven asia pacif america off-set emea hip price
versu volum versu benefit
improv sale across key product intern growth product suppli
constrain off-set impact warsaw north campu suppli constraint
appear steadili improv
sport medicin extrem trauma set sale versu
compar estim set price versu
volum versu benefit broad-bas growth
across variou product line off-set suppli constraint sport medicin
spine craniomaxillofaci cmf sale versu
compar estim spine cmf price versu
volum versu benefit cmf
thorac product uptak off-set spine impact us salesforc integr dis-
dental sale versu compar estim
dental price versu volum versu
continu work portfolio realign continu face challeng
sale reorgan certain geographi
rosa robot recent receiv clearanc brain surgeri applic rosa manag
note call limit launch rosa tka rosa spine still plan late
full launch import given robot key part compani competit
posit much focu rosa meet timelin limit launch
price target nc
price target base approxim cash ep estim risk
thesi includ increas invest slower procedur volum growth price pressur
disrupt integr biomet
zimmer biomet share trade discount large-cap med-tech peer group believ
discount narrow next twelv month compani benefit leadership
new commercially-driven ceo bryan hanson oper issu resolv pipelin
begin fulli appreci
warsaw indiana-bas zimmer biomet hold one world largest orthoped implant
manufactur compani global market leader billion reconstruct orthoped
implant busi hip knee implant togeth account roughli revenu
compani report sale billion
